These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22693252)

  • 61. The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.
    Yu L; Favoino E; Wang Y; Ma Y; Deng X; Wang X
    Immunol Res; 2011 Aug; 50(2-3):294-302. PubMed ID: 21717063
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
    Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
    EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
    Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
    Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S; Puzanov I
    Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
    Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
    Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
    Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.
    Kugel CH; Hartsough EJ; Davies MA; Setiady YY; Aplin AE
    Cancer Res; 2014 Aug; 74(15):4122-32. PubMed ID: 25035390
    [TBL] [Abstract][Full Text] [Related]  

  • 68. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition.
    Fernandez M; Sutterlüty-Fall H; Schwärzler C; Lemeille S; Boehncke WH; Merat R
    Cancer Med; 2017 Jul; 6(7):1652-1664. PubMed ID: 28573821
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
    Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
    Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vemurafenib.
    Flaherty KT; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Oct; 10(11):811-2. PubMed ID: 22037033
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
    Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.
    Wood K; Luke JJ
    Curr Oncol Rep; 2016 Nov; 18(11):67. PubMed ID: 27613168
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
    Jang S; Atkins MB
    Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
    Bollag G; Hirth P; Tsai J; Zhang J; Ibrahim PN; Cho H; Spevak W; Zhang C; Zhang Y; Habets G; Burton EA; Wong B; Tsang G; West BL; Powell B; Shellooe R; Marimuthu A; Nguyen H; Zhang KY; Artis DR; Schlessinger J; Su F; Higgins B; Iyer R; D'Andrea K; Koehler A; Stumm M; Lin PS; Lee RJ; Grippo J; Puzanov I; Kim KB; Ribas A; McArthur GA; Sosman JA; Chapman PB; Flaherty KT; Xu X; Nathanson KL; Nolop K
    Nature; 2010 Sep; 467(7315):596-9. PubMed ID: 20823850
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Wang W; Kang H; Zhao Y; Min I; Wyrwas B; Moore M; Teng L; Zarnegar R; Jiang X; Fahey TJ
    J Clin Endocrinol Metab; 2017 Feb; 102(2):634-643. PubMed ID: 27754804
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
    Lou Y; Wang G; Lizée G; Kim GJ; Finkelstein SE; Feng C; Restifo NP; Hwu P
    Cancer Res; 2004 Sep; 64(18):6783-90. PubMed ID: 15374997
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
    Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
    Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.
    Mok S; Koya RC; Tsui C; Xu J; Robert L; Wu L; Graeber T; West BL; Bollag G; Ribas A
    Cancer Res; 2014 Jan; 74(1):153-161. PubMed ID: 24247719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.